This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Orly Uri was appointed as a Director at BrainsWay in December 2018.
Mrs. Uri is a financial, strategic and organizational advisor to organizations and corporations in the healthcare sector.
Prior to that she served as head of planning, budgeting and economics department in Leumit HMO between 1996 and 2003.
Mrs. Uri earned a BA in Economics and Business Administration and a M.Sc. in Industrial and Management Engineering—Medical Management, both from Ben Gurion University.
With over 30 years of experience in the healthcare sector, Mrs. Uri provides broad and experienced knowledge of the healthcare industry.